OTCMKTS:IMUN Immune Therapeutics (IMUN) Stock Price, News & Analysis → 2024 Oil Boom (From The Oxford Club) (Ad) Free IMUN Stock Alerts $0.09 0.00 (0.00%) (As of 10/19/2023) Add Compare Share Share Today's Range$0.09▼$0.0950-Day Range$0.09▼$0.0952-Week Range$0.07▼$1.30Volume12 shsAverage Volume15,246 shsMarket Capitalization$7.78 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisHeadlinesStock AnalysisHeadlines Get Immune Therapeutics alerts: Email Address Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Immune Therapeutics Stock (OTCMKTS:IMUN)Immune Therapeutics, Inc. does not have significant operations. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in October 2014. Immune Therapeutics, Inc. is based in Winter Park, Florida.Read More IMUN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMUN Stock News HeadlinesMay 4, 2024 | americanbankingnews.comCritical Analysis: Vincerx Pharma (NASDAQ:VINC) vs. Immune Therapeutics (OTCMKTS:IMUN)May 2, 2024 | msn.comResearchers discover how immune B cells hunt down cancer around the bodyMay 6, 2024 | DTI (Ad)The best inflation-proof investment The markets are CRAZY right now. Which is why thousands of investors are flocking into one little-known company. May 2, 2024 | msn.comControlled human infection study paves the way to improving vaccines and therapeutics developmentApril 29, 2024 | markets.businessinsider.comRepertoire Immune Medicines In Strategic Partnership With Bristol Myers SquibbApril 26, 2024 | msn.comExperts develop immune-enhancing therapies to target tuberculosisApril 25, 2024 | benzinga.comEXCLUSIVE: Virax Biolabs Launches Immune Profiling Solutions To Evaluate Adaptive Immunity In Post-Viral SyndromesApril 22, 2024 | msn.comSupreme Court Will Decide Whether Trump Is Immune From Federal Prosecution. Here's What's NextMay 6, 2024 | DTI (Ad)The best inflation-proof investment The markets are CRAZY right now. Which is why thousands of investors are flocking into one little-known company. April 11, 2024 | msn.comThese Stocks Are Moving the Most Today: Alpine Immune, CarMax, Robinhood, Fastenal, Nike, Constellation Brands, and MoreApril 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Alpine Immune Sciences Amid Positive Clinical Trial ResultsApril 8, 2024 | msn.comRogue immune cell that can cause poor antibody responses in chronic viral infections discoveredApril 5, 2024 | finance.yahoo.comImmunis Discusses with Experts Why the Immune System is the Key to Human HealthspanMarch 31, 2024 | msn.comResearchers identify new way to inhibit immune cells that drive allergic asthmaMarch 29, 2024 | finance.yahoo.comBIRM Is Using Nature to Balance the Immune SystemMarch 25, 2024 | usnews.comRussian Security Failure? Kremlin Says No Country Is Immune to TerrorismMarch 21, 2024 | msn.comScientists shed light on key immune regulators involved in Alzheimer’s and other disorders of lipid-rich tissuesMarch 19, 2024 | msn.comEmpty 'backpacks' attached to neutrophils activate the immune system against cancerMarch 19, 2024 | msn.comNew drug candidates could 'unmask' HIV-infected cells that evade the immune systemMarch 18, 2024 | msn.comNew Medical Breakthrough: Innovative Application of Immune ProteinMarch 11, 2024 | msn.comRevolutionary Breakthrough: Unraveling the Role of an Immune Protein with Therapeutic PotentialMarch 7, 2024 | msn.comA Key to Immunity Unlocked: How a Novel Discovery of an Immune Protein Opens Up New Possibilities for HealingMarch 4, 2024 | msn.comImmune Protein’s Novel Use: A Leap Forward in Medical TreatmentMarch 4, 2024 | msn.comImmune Protein’s Newly Found Role May Pave Way for Groundbreaking Medical AdvancesFebruary 26, 2024 | msn.comA groundbreaking discovery: the function of an immune protein, opening up new possibilities for revolutionary therapiesFebruary 22, 2024 | msn.comImmune cell receptor provides promising immunotherapy targetFebruary 22, 2024 | msn.comHow an immune protein works: a breakthrough finding with potential for radical therapiesSee More Headlines Receive IMUN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:IMUN CUSIPN/A CIK1559356 Webwww.immunetherapeutics.com Phone(888) 613-8802FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,540,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-544.75% Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.03) per share Price / Book-3.10Miscellaneous Outstanding Shares83,660,000Free Float41,335,000Market Cap$7.78 million OptionableNot Optionable Beta0.46 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMs. Kelly O'Brien Wilson (Age 51)Interim CEO, COO & Pres Comp: $53.83kMs. Noreen M. Griffin (Age 70)Exec. VP of Bus. Devel. & CEO Mr. Glen A. Farmer M.B.A. (Age 54)Chief Financial Officer Ms. Cynthia Douglas (Age 50)Company Sec. Dr. Joseph M. Fortunak (Age 68)VP of Global R&D and Chemical Devel. Key CompetitorsCyclerion TherapeuticsNASDAQ:CYCNMedicureOTCMKTS:MCUJFTenax TherapeuticsNASDAQ:TENXVaccinexNASDAQ:VCNXChemomab TherapeuticsNASDAQ:CMMBView All Competitors IMUN Stock Analysis - Frequently Asked Questions How have IMUN shares performed in 2024? Immune Therapeutics' stock was trading at $0.0930 at the beginning of 2024. Since then, IMUN stock has increased by 0.0% and is now trading at $0.0930. View the best growth stocks for 2024 here. What other stocks do shareholders of Immune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immune Therapeutics investors own include Northwest Biotherapeutics (NWBO), Alexion Pharmaceuticals (ALXN), AK Steel (AKS), Galiano Gold (AKG), Agritek (AGTK), Agenus (AGEN), Affymetrix (AFFX), Advanced Disposal Services (ADSW), Adamis Pharmaceuticals (ADMP) and Analog Devices (ADI). How do I buy shares of Immune Therapeutics? Shares of IMUN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:IMUN) was last updated on 5/6/2024 by MarketBeat.com Staff From Our PartnersNo experience to confident trader, meet my student…Wealth Builders InstituteBiden’s $374B Giveaway Into This SectorDTIAI “wealth window” is closing June 25thParadigm Press2024 Oil BoomThe Oxford ClubMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceThe 2024 crypto bull run has already started — don’t get left behindInvestorPlaceThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immune Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
